Carmen Argmann, PhD Email Carmen Argmann
- ASSOCIATE PROFESSOR | Genetics and Genomic Sciences
Dr. Argmann has a doctorate from the faculty of Science at the University of Western Ontario, Canada where she showed that PPARγ and LXR activation could dramatically reduce macrophage foam cell formation, a key event in atherosclerosis. During her postdoctoral studies at the Institut de Génétique et de Biologie Moléculaire et Cellulaire in Strasbourg, France she contributed to the development of high-throughput mouse metabolic phenotyping protocols and demonstrated that resveratrol, a compound found in red wine, improves mitochondrial function and protects against metabolic disease in vivo.
As a research scientist in Dr Schadt’s genetics group at Rosetta Inpharmatics she contributed to the designing of large-scale genetic mouse crosses to address novel facets of metabolic disease. She was involved in integrating DNA variation, gene expression, and clinical data collected, in order to uncover core networks associated with metabolic disease processes, which in turn were used to identify novel therapeutic targets for the Diabetes and Obesity franchise.
In 2010, during her time in Dr. Aerts’s lab at the Academic Medical Center of the University of Amsterdam, she developed further into an integrative biologist. Her main focus has become applying novel integrative systems biology approaches to understand the hallmarks and key drivers of various human diseases.
Since 2013, she has been an assistant professor at Mount Sinai in the Icahn Institute for Data Science and Genomic Technology (formerly the Icahn Institute for Genomics and Multiscale Biology) and is actively applying her integrative biology approaches in various large scale collaborations associated with: generating network models in inflammatory bowel disease; finding novel human beta cell regeneration strategies for Type 2 Diabetes and uncovering genetic modifiers of screenable inborn errors of metabolism.
Figure: Example schema of the integrative approaches applied to understanding disease processes.
Currently we have one postdoctoral position available. Please contact me at firstname.lastname@example.org
Multi-Disciplinary Training Area
Genetics and Data Science [GDS]
PhD, University of Western Ontario
Project 3: Generating predictive network models for Inflammatory Bowel Disease (IBD):
Background: Inflammatory bowel disease (IBD) involves chronic inflammation of all or part of your digestive tract and primarily includes ulcerative colitis and Crohn's disease. IBD can be debilitating with severe diarrhea, pain, fatigue and weight loss and is sometimes associated with life-threatening complications. Currently there is an unmet therapeutic need with many patients either non-responsive or refractory to current treatment options. MSSM from the clinic, to preclinical models to computational modelers have extensive expertise in IBD. Because of this expertise Janssen pharmaceuticals in 2013 entered into a multi-million dollar collaboration with MSSM clinicians, preclinical scientists and computational biologists to generate new patient information, understand preclinical IBD mouse models and computational interpret all the data as predictive networks of IBD.
Hypothesis: The underlying hypothesis we are testing is that the through multi-scale modeling of IBD patient derived molecular insights that we can better understand the disease pathology and predict candidate novel genes and biology for potential therapeutic development. I have been involved in various aspects of this collaboration using my integrative biologist skill set to help generate data for and interpret the networks.
Impact: Data driven models have proven effective in understanding other complex diseases (Diabetes, obesity CVD) thus the application of these models to IBD is a much needed complementary approach to interpreting a very complex disease process.
For a complete list of Dr. Argmann's publications http://www.ncbi.nlm.nih.gov/pubmed/?term=argmann+C
Project 2: Learning about human beta cell regeneration by integrating molecular landscapes of human insulinomas
Background: Adult human beta cells have proven remarkably resistant to therapeutic replication and expansion. This has significantly limited therapeutic options for Type 1 and 2 diabetics, both types which result entirely or in part from a deficiency of normal insulin-producing pancreatic beta cells.
Hypothesis/Aims: This knowledge gap has prompted an extensive search for strategies to regenerate or replace lost or dysfunctional beta cells. An intriguing, unexplored proliferative model is insulinoma, rare tumors of the adult beta cell. With this rationale, Dr Andrew Stewart (Director of the Diabetes and Obesity Institute at MSSM) initiated a collaboration with myself, Dr Bojan Losic (MSSM GGS faculty) and Dr Eric Schadt (Director of the Icahn Institute for Multi-Scale Biology and GGS department) in order to perform the first comprehensive genomic and transcriptomic characterization of human insulinomas. We are then integrating these molecular landscapes with those of normal beta cell transcriptomes in order to reveal underlying biological processes in insulinomas including proliferation mechanisms. Several predicted cell cycle gene candidates are being experimentally confirmed.
Impact: Overall our integrative approach hopes to uncover the key hallmarks and drivers of human insulinoma which distinguish them from normal beta cells and may serve as therapeutic targets for the diabetes field.
Project 1: Innovative data-driven multiscale biology approaches to discover modifiers of screenable disorders in newborns
Background: Inborn errors of metabolism (IEM) are increasingly viewed as complex diseases as they often present as a spectrum of disease phenotypes with a clear disconnect between the severity of mutation at the primary affected locus and the phenotype. The lack of genotype and phenotype correlation greatly impacts the ability to predict a patient’s disease course. It also illustrates the existence of a fundamental gap in our knowledge of disease pathophysiology. The era of one-gene one-disease is being abandoned, and the contribution of modifying factors considered. However, identifying the modifying factors is not trivial, as rare diseases have rare data.
Hypothesis: We hypothesize that by embracing the concept of IEM as complex diseases that 1. datasets and 2. network approaches generated in populations with common disorders can be used to study disease modifying biology in IEM thereby overcoming the rare disease rare data drawback. Our strategy is based on observing that differentially expressed genes from IEM experimental models highlight highly connected subnetworks in the molecular networks established in common disease populations.
Aim: Our lab’s aim is to use our innovative data-driven multi-scale computational approach to derive and then wet-lab validate novel candidate modifying genes and their associated biology related to the screenable inborn errors of fatty acid oxidation (FAO) the lysosomal storage disorder, Gaucher disease (GD). This is a key collaboration between myself and a faculty expert in IEM, Dr Sander Houten, also of the Department of Genetics and Genomics Sciences at ICAHN.
Impact: Combined these two aims will break new ground for FAO and GD and rare diseases in general by overcoming inherent limitations of rare data through combining novel methodologies with existing data. We furthermore perform validations and these methods which could point the IEM research field into multiple new directions. These novel insights are needed to propel the IEM field into the next generation of understanding.
Identifying novel biological insights on complex human diseases requires spanning both the biological and computational worlds. Our biological data mining strategies aim to do this by helping to ask the right computational questions in order to get the right biological answers.
One major part of our group’s research is to facilitate generation of large scale datasets which can be integrated into causal predictive molecular networks which we then interpret for the pathophysiology of underlying complex biological questions. Our network insights are refined into candidate genes and pathways and formulated into testable hypotheses, some of which we perform experimental validation of ourselves.
Ultimately we aim to use this knowledge to predict novel therapeutic candidates for diseases of interest. We have applied these methods in multiple disciplines covering complex diseases (metabolic syndrome, IBD and cancer), complex traits (aging) as well as inborn errors of metabolism (Gaucher’s disease and Mitochondrial disorders).
Our system biology approaches are highly collaborative projects as they require various expertise from clinicians in the clinic, to experimentalist in the wet lab to the computational analyst in the dry lab. Three of my group’s main projects are summarized:
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr.Argmann did not report having any of the following types of financial relationships with industry during 2018 and/or 2019: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.